New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nature medicine Chertow, G. M., Chang, A. M., Felker, G. M., Heise, M., Velkoska, E., Fellström, B., Charytan, D. M., Clementi, R., Gibson, C. M., Goodman, S. G., Jardine, M., Levin, A., Lokhnygina, Y., Mears, J., Mehran, R., Stenvinkel, P., Wang, A., Wheeler, D. C., Zoccali, C., Ridker, P. M., Mahaffey, K. W., Tricoci, P., Wolf, M. 2024Abstract
Inflammation mediated by interleukin-6 (IL-6) is strongly associated with cardiovascular risk. Here we evaluated clazakizumab, a monoclonal antibody targeting the IL-6 ligand, in a phase 2b dose-finding study. Adults with cardiovascular disease and/or diabetes receiving maintenance dialysis with high-sensitivity C-reactive protein (hs-CRP)?=?2?mg?l-1 at baseline were randomized to receive clazakizumab (2.5?mg, 5?mg or 10?mg, n?=?32 per dose group) or placebo (n?=?31) every 4?weeks. The primary endpoint was the change from baseline in hs-CRP to week 12, expressed as the geometric mean ratio. Clazakizumab treatment signficantly reduced serum hs-CRP concentrations at week 12 by 86%, 90% and 92% relative to placebo in patients randomized to 2.5?mg, 5?mg or 10?mg clazakizumab, respectively (all P?
View details for DOI 10.1038/s41591-024-03043-1
View details for PubMedID 38796655
View details for PubMedCentralID 3145073